Neurocrine Biosciences Company Profile (NASDAQ:NBIX)

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.67) by $0.01. The company had revenue of $6.34 million for the quarter, compared to analysts' expectations of $0.61 million. During the same period in the previous year, the business earned ($0.46) EPS. View Neurocrine Biosciences' Earnings History.

17 brokers have issued 12-month price targets for Neurocrine Biosciences' stock. Their predictions range from $55.00 to $100.00. On average, they expect Neurocrine Biosciences' share price to reach $68.25 in the next year. View Analyst Ratings for Neurocrine Biosciences.

Here are some recent quotes from research analysts about Neurocrine Biosciences stock:

• 1. Cowen and Company analysts commented, "NBIX remains well funded, ending Q4 with $352MM in cash." (2/15/2017)
• 2. Robert W. Baird analysts commented, "No change to outlook heading into Ingrezza approval. Neurocrine reported a solid end to the year, modestly beating estimates on lower-than-expected opex. Though we are only a few weeks into 2017, it has already been a busy year for NBIX. Expect the year to continue to bring multiple updates, from potential approval of Ingrezza in TD and Tourette data in May to Phase 3 UF data for elagolix near year-end, an elagolix NDA submission, advances in CAH and essential tremor, and FDA discussions on newly licensed opicapone' Earnings and spend in-line, expect accelerations into launch. 4Q16 EPS of ($0.51) modestly beat our/consensus estimates of ($0.54)/($0.57), respectively, due to lower than projected operating expenses. Looking ahead to 2017, management expects opex to increase to about $230M-$240M due activities surrounding the launch of Ingrezza." (2/15/2017)
• 3. Needham & Company LLC analysts commented, "Company continues to prepare for Ingrezza launch ahead of 4/11/17 PDUFA date. We expect approval based on strength of Phase 3 data, followed by launch ~6wks later. We believe Boxed Warning/ REMS are possible. Phase 2 pediatric Tourette Syndrome (TS) data are expected May 2017 (was Apr). Given efficacy trend observed in adult Phase 2 TS, we believe Ingrezza will likely be active in pediatric TS as well. Elagolix NDA submission for Endometriosis by Abbvie is expected 3Q17 (was 2H17), triggering a $30M payment to Neurocrine. Phase 3 results in Uterine Fibroids are expected by YE17. We believe stock is attractive ahead of near term events. BUY." (2/10/2017)
• 4. HC Wainwright analysts commented, "We expect FDA to agree in early 2017 that Atara has demonstrated comparability between clinical batches of ATA-129, or EBV-CTL, and the prior material produced at MSKCC, paving the way for Phase 3 start. We believe comparability data will include the number of cells to administer, cytoreactivity, cell storage time, restriction studies (HLA types), variability based on release criteria, and the methods by which data are collected. CMC amendment standard for new clinical material Importantly, a CMC amendment is standard practice for an IND when new clinical material is introduced; therefore, we view Atara’s process as normal." (1/18/2017)
• 5. Jefferies Group LLC analysts commented, "While the study showed a stat sig improvement on the Clinical Global Impression of Change scale (CGI; p=0.015), the study did not reach stat sig on the 1EP of Yale Global Tic Severity Scale (YGTSS; p=0.18). No further trial details were released. Although a setback, we note that this does not directly read through to the pediatric study readout expected in April." (1/18/2017)

Some companies that are related to Neurocrine Biosciences include Kite Pharma (KITE), Exelixis (EXEL), TESARO (TSRO), Bioverativ (BIVV), bluebird bio (BLUE), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), AveXis (AVXS), Sarepta Therapeutics (SRPT), GW Pharmaceuticals PLC (GWPH), Spark Therapeutics (ONCE), Axovant Sciences Ltd (AXON), Prothena Corporation PLC (PRTA), China Biologic Products (CBPO), Halozyme Therapeutics (HALO) and Loxo Oncology (LOXO).

Neurocrine Biosciences' management team includes the folowing people:

• William H. Rastetter Ph.D., Independent Chairman of the Board
• David-Alexandre C. Gros M.D., President, Interim Chief Financial Officer, Chief Operating Officer
• Kevin C. Gorman Ph.D., Chief Executive Officer, Director
• Eric S. Benevich, Chief Commercial Officer
• Haig P. Bozigian Ph.D., Chief Development Officer
• Kyle Gano Ph.D., Chief Business Development Officer
• Dimitri E. Grigoriadis Ph.D., Chief Research Officer
• Malcolm Lloyd-Smith, Chief Regulatory Officer
• Christopher F. O'Brien M.D., Chief Medical Officer
• Darin M. Lippoldt, Corporate Secretary

Neurocrine Biosciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Vanguard Group Inc. (7.86%), Janus Henderson Group PLC (6.08%), BlackRock Inc. (5.45%), PERCEPTIVE ADVISORS LLC (5.30%) and BB Biotech AG (3.91%). Company insiders that own Neurocrine Biosciences stock include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Richard F Pops, Timothy P Coughlin and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences.

Neurocrine Biosciences' stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Sectoral Asset Management Inc, Jennison Associates LLC, Marshall Wace North America L.P., BlackRock Inc., JPMorgan Chase & Co., Emerald Advisers Inc. PA and Capital World Investors. Company insiders that have sold Neurocrine Biosciences stock in the last year include Christopher Flint Obrien, Corinne H Nevinny, Dimitri E Grigoriadis, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Timothy P Coughlin and William H Rastetter. View Insider Buying and Selling for Neurocrine Biosciences.

Neurocrine Biosciences' stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, TimesSquare Capital Management LLC, HealthCor Management L.P., FMR LLC, Goldman Sachs Group Inc., Senzar Asset Management LLC, Franklin Resources Inc. and Wells Fargo & Company MN. View Insider Buying and Selling for Neurocrine Biosciences.

Shares of Neurocrine Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Neurocrine Biosciences stock can currently be purchased for approximately $58.96.